| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 2,800 | 4,530 | 5,720 | 5,750 | 4,780 |
| Sales Growth | -38.19% | -20.80% | -0.52% | +20.29% | unch |
| Net Income | -115,180 | -103,110 | -110,570 | -104,900 | -100,960 |
| Net Income Growth | -11.71% | +6.75% | -5.41% | -3.90% | -603.55% |
Absci Corp (ABSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Absci Corporation is a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design. Absci Corporation is based in NEW YORK.
Fiscal Year End Date: 12/31